| Literature DB >> 24489943 |
Wei Li1, Guangju Teng2, Hongfei Tong3, Yanmei Jiao1, Tong Zhang1, Hui Chen4, Hao Wu1.
Abstract
BACKGROUND: Epidemics of HFMD are elevated every year globally, especially in mainland China. The disease now presents as an increasing threat to public health worldwide.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24489943 PMCID: PMC3906182 DOI: 10.1371/journal.pone.0087603
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient characteristics.
| Total (n = 571) | Mild (n = 221) | Severe (n = 350) | |
| Age (year) | 2.58±1.80 | 3.64±1.70 | 1.87±1.98 |
| Gender (Male/Female) | 351/220 | 151/70 | 200/150 |
| Weight (kg) | 14.06±6.60 | 18.11±7.89 | 12.56±8.86 |
| RR (/min) | 28.14±5.63 | 26.10±6.13 | 32.01±6.76 |
| Temperature (°C) | 37.67±0.92 | 36.54±0.77 | 38.23±0.78 |
| Pulse (/min) | 123.12±16.83 | 117.34±16.56 | 129.61±18.99 |
| Systolic pressure (mmHg) | 101.45±11.35 | 95.33±21.33 | 107.54±23.54 |
| Diastolic pressure (mmHg) | 69.99±9.05 | 62.66±13.51 | 77.76±31.45 |
| GLU (mmol/L) | 6.30±2.50 | 5.52±3.12 | 7.83±2.92 |
| WBC (109/L) | 11.18±4.43 | 9.33±3.12 | 13.83±4.24 |
| Neutrophils (%) | 56.45±18.11 | 51.09±20.65 | 60.09±22.94 |
| Lymphocytes (%) | 35.94±16.52 | 33.21±21.21 | 38.46±17.92 |
| HB (g/dL) | 119.08±12.34 | 118.92±22.01 | 119.66±31.28 |
| PLT (109/L) | 313.23±91.44 | 310.11±98.10 | 312.92±101.31 |
| ALT (IU/L) | 21.86±35.21 | 20.21±30.22 | 23.54±29.35 |
| AST (IU/L) | 37.91±21.06 | 35.87±20.92 | 37.84±32.12 |
| CK (IU/L) | 144.11±193.71 | 152.42±200.12 | 142.98±188.72 |
| CK-MB (IU/L) | 16.51±26.20 | 20.48±21.32 | 15.89±34.02 |
| CRP (mg/L) | 3.61±4.14 | 3.24±5.22 | 3.77±3.89 |
| LDH (U/L) | 260.17±74.62 | 258.11±85.32 | 268.39±74.66 |
| K (mmol/L) | 4.29±1.02 | 4.35±1.08 | 4.22±1.31 |
| Na (mmol/L) | 136.17±3.76 | 138.56±3.98 | 135.09±4.22 |
| CL (mmol/L) | 101.67±41.80 | 104.27±40.96 | 95.38±39.69 |
RR: respiratory rate, GLU: blood glucose, LYM: percentage of lymphocytes, ALT: alanine aminotransferase, CL: blood chlorine, WBC: white blood cell counts, CK: creatine kinase, CK-MB: creatine kinase-MB, CRP: C-reactive protein, LDH: Lactate dehydrogenase.
Risk factors for severe HFMD cases.
| P value | ||
| Univariate analysis | Multivariate analysis | |
| RR>26/min | <0.001 | <0.001 |
| Age<4 yo | 0.001 | <0.001 |
| GLU>8.3 mmol/L | 0.008 | 0.011 |
| LYM>40% | 0.075 | 0.010 |
| ALT>40 U/L | 0.099 | 0.045 |
| CL<98 mmol/L | 0.026 | |
| WBC>1.2×109/L | 0.040 | |
| Fever>38.5°C | 0.055 | |
RR: respiratory rate, GLU: blood glucose, LYM: percentage of lymphocytes, ALT: alanine aminotransferase, CL: blood chlorine, WBC: white blood cell counts.
Figure 1Directed correlation web of risk factors and disease severity.
The percentages of coexistence of two factors among all selected cases were shown in the form of directed correlation web. The line thickness indicates the rates of coexistence. Bold line: Rate of coexistence of two linked factors among all cases is >50%; Thin line: Rate of coexistence of two linked factors among all cases is 30%–50%; Dash line: Rate of coexistence of two linked factors among all cases is <30%. RR: respiratory rate (/min), GLU: blood glucose (mmol/L), LYM: percentage of lymphocytes (%), ALT: alanine aminotransferase (U/L), CL: blood chlorine (mmol/L), WBC: white blood cell counts (109/L).
Combinations of risk factors.
| Combinations | Case# (n) | Popularity (%) | CR (%) | Support (%) |
| GLU>8.3 and CL<98 and RR>26 | 12 | 2.1 | 100.0 | 2.1 |
| ALT>40 and LYM>40% and RR>26 and Age<4 yo | 14 | 2.5 | 92.9 | 2.3 |
| GLU>8.3 and CL<98 | 16 | 2.8 | 87.5 | 2.5 |
| GLU>8.3 and WBC>1.2 and RR>26 | 16 | 2.8 | 87.5 | 2.5 |
| GLU>8.3 and RR>26 | 31 | 5.5 | 87.1 | 4.8 |
| GLU>8.3 and LYM>40% and RR>26 | 23 | 4.1 | 87.0 | 3.5 |
| ALT>40 and LYM>40% and RR>26 | 15 | 2.6 | 86.7 | 2.3 |
| GLU>8.3 and WBC>1.2 and RR>26 and Age<4 yo | 15 | 2.6 | 86.7 | 2.3 |
| GLU>8.3 and CL<98 and Age<4 yo | 14 | 2.5 | 85.7 | 2.1 |
| GLU>8.3 and RR>26 and Age<4 yo | 28 | 4.9 | 85.7 | 4.2 |
| GLU>8.3 and WBC>1.2 and LYM>40% and RR>26 | 14 | 2.5 | 85.7 | 2.1 |
| GLU>8.3 and LYM>40% and RR>26 and Age<4 yo | 21 | 3.7 | 85.7 | 3.2 |
| GLU>8.3 and WBC>1.2 and LYM>40% and RR>26 and Age<4 yo | 13 | 2.3 | 84.6 | 1.9 |
| GLU>8.3 and LYM>40% | 31 | 5.5 | 83.9 | 4.6 |
| ALT>40 and RR>26 and Age<4 yo | 24 | 4.2 | 83.3 | 3.5 |
| GLU>8.3 and WBC>1.2 and LYM>40% | 18 | 3.2 | 83.3 | 2.6 |
| CL<98 and WBC>1.2 and LYM>40% and RR>26 | 23 | 4.1 | 82.6 | 3.4 |
| ALT>40 and LYM>40% and Age<4 yo | 17 | 3.0 | 82.4 | 2.5 |
| GLU>8.3 and WBC>1.2 and LYM>40% and Age<4 yo | 17 | 3.0 | 82.4 | 2.5 |
| GLU>8.3 and LYM>40% and Age<4 yo | 28 | 4.9 | 82.1 | 4.1 |
| CL<98 and WBC>1.2 and LYM>40% and RR>26 and Age<4 yo | 22 | 3.9 | 81.8 | 3.2 |
| GLU>8.3 and WBC>1.2 | 21 | 3.7 | 81.0 | 3.0 |
| CL<98 and LYM>40% and RR>26 and Age<4 yo | 73 | 12.9 | 80.8 | 10.4 |
| CL<98 and WBC>1.2 and LYM>40% | 31 | 5.5 | 80.6 | 4.4 |
| ALT>40 and RR>26 | 25 | 4.4 | 80.0 | 3.5 |
| GLU>8.3 and WBC>1.2 and Age<4 yo | 20 | 3.5 | 80.0 | 2.8 |
| GLU>8.3 | 43 | 7.6 | 79.1 | 6.0 |
| CL<98 and WBC>1.2 and LYM>40% and Age<4 yo | 28 | 4.9 | 78.6 | 3.9 |
| ALT>40 and WBC>1.2 | 18 | 3.2 | 77.8 | 2.5 |
| ALT>40 and LYM>40% | 18 | 3.2 | 77.8 | 2.5 |
| LYM>40% and RR>26 and Age<4 yo | 191 | 33.7 | 77.5 | 26.1 |
| WBC>1.2 and LYM>40% and RR>26 and Age<4 yo | 75 | 13.2 | 77.3 | 10.2 |
| ALT>40 and WBC>1.2 and RR>26 | 13 | 2.3 | 76.9 | 1.8 |
| ALT>40 and WBC>1.2 and RR>26 and Age<4 yo | 13 | 2.3 | 76.9 | 1.8 |
| ALT>40 and WBC>1.2 and Age<4 yo | 17 | 3.0 | 76.5 | 2.3 |
| GLU>8.3 and Age<4 yo | 38 | 6.7 | 76.3 | 5.1 |
| CL<98 and LYM>40% and RR>26 | 80 | 14.1 | 76.3 | 10.8 |
| CL<98 and LYM>40% and Age<4 yo | 92 | 16.2 | 76.1 | 12.3 |
| ALT>40 and Age<4 yo | 33 | 5.8 | 75.8 | 4.4 |
| WBC>1.2 and LYM>40% and RR>26 | 82 | 14.5 | 75.6 | 10.9 |
| CL<98 and RR>26 and Age<4 yo | 111 | 19.6 | 73.9 | 14.5 |
| CL<98 and WBC>1.2 and RR>26 | 38 | 6.7 | 73.7 | 4.9 |
| WBC>1.2 and RR>26 and Age<4 yo | 127 | 22.4 | 73.2 | 16.4 |
| LYM>40% and RR>26 | 215 | 37.9 | 73.0 | 27.7 |
| CL<98 and WBC>1.2 and RR>26 and Age<4 yo | 37 | 6.5 | 73.0 | 4.8 |
| WBC>1.2 and RR>26 | 134 | 23.6 | 72.4 | 17.1 |
| ALT>40 | 36 | 6.3 | 72.2 | 4.6 |
| CL<98 and WBC>1.2 | 54 | 9.5 | 72.2 | 6.9 |
| WBC>1.2 and LYM>40% and Age<4 yo | 104 | 18.3 | 72.1 | 13.2 |
| CL<98 and LYM>40% | 111 | 19.6 | 72.1 | 14.1 |
| CL<98 and RR>26 | 119 | 21.0 | 71.4 | 15.0 |
| RR>26 and Age<4 yo | 336 | 59.3 | 71.4 | 42.3 |
| LYM>40% and Age<4 yo | 265 | 46.7 | 71.3 | 33.3 |
| WBC>1.2 and LYM>40% | 118 | 20.8 | 70.3 | 14.6 |
| CL<98 and WBC>1.2 and Age<4 yo | 50 | 8.8 | 70.0 | 6.2 |
RR: respiratory rate (/min), GLU: blood glucose (mmol/L), LYM: percentage of lymphocytes (%), ALT: alanine aminotransferase (U/L), CL: blood chlorine (mmol/L), WBC: white blood cell counts (109/L), CR: Confidence ratio
Figure 2Correlation web on correlations among risk factors and severe cases.
The percentages of coexistence of two factors among all selected cases were shown in the form of correlation web. The line thickness indicates the rates of coexistence. Bold line: Rate of coexistence of two linked factors among all cases is >40%; Thin line: Rate of coexistence of two linked factors among all cases is 15%–40%; Dash line: Rate of coexistence of two linked factors among all cases is <15%. RR: respiratory rate (/min), GLU: blood glucose (mmol/L), LYM: percentage of lymphocytes (%), ALT: alanine aminotransferase (U/L), CL: blood chlorine (mmol/L), WBC: white blood cell counts (109/L).
Correlations between cytokine levels and disease severity.
| Mild (n = 221) | Severe (n = 350) | P value | |||||
| Median | Quartile range | Median | Quartile range | ||||
| IL2 | 5.33 | 3.25 | 9.13 | 9.40 | 4.09 | 16.23 | 0.006 |
| IL4 | 0.68 | 0.49 | 1.02 | 0.90 | 0.66 | 1.26 | 0.003 |
| IL6 | 11.90 | 6.54 | 22.97 | 18.02 | 6.89 | 43.61 | 0.104 |
| IL10 | 5.90 | 3.98 | 11.65 | 8.11 | 5.04 | 24.33 | 0.041 |
| IFNγ | 70.92 | 43.96 | 182.86 | 124.62 | 86.53 | 198.85 | 0.004 |
| GMCSF | 14.06 | 10.93 | 28.15 | 18.95 | 12.26 | 30.77 | 0.029 |
| TNFα | 17.00 | 13.07 | 39.23 | 30.04 | 15.27 | 88.34 | 0.008 |